Collagen VI in cancer and its biological mechanisms

Trends in Molecular Medicine

Volumn 19, Issue 7, 2013, Pages 410-417

  Chen, Peiwen ^a   Cescon, Matilde ^a   Bonaldo, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

angiogenesis; cancer; chemotherapy resistance; collagen VI; inflammation; therapeutic target

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CISPLATIN; COLLAGEN TYPE 6; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; LYMPHOID ENHANCER FACTOR 1; METALLOTHIONEIN; OXALIPLATIN; PROTEIN KINASE B; T CELL FACTOR PROTEIN;

ANGIOGENESIS; ASTROCYTOMA; BREAST CANCER; CANCER DIAGNOSIS; CANCER RESISTANCE; CHEMOTHERAPY; COLON CANCER; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CANCER; GLIOBLASTOMA; HUMAN; INFLAMMATION; LUNG CANCER; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; NASOPHARYNX FIBROMA; NEUROFIBROMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; COLLAGEN TYPE VI; DRUG RESISTANCE, NEOPLASM; HUMANS; INFLAMMATION; MACROPHAGES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84879786570     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.04.001     Document Type: Review

References (88)

1. Lu P., et al. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
2. Bernardi P., Bonaldo P. Dysfunction of mitochondria and sarcoplasmic reticulum in the pathogenesis of collagen VI muscular dystrophies. Ann. N. Y. Acad. Sci. 2008, 1147:303-311.
3. Bonaldo P., et al. Structural and functional features of the alpha 3 chain indicate a bridging role for chicken collagen VI in connective tissues. Biochemistry 1990, 29:1245-1254.
4. Aigner T., et al. The C5 domain of Col6A3 is cleaved off from the Col6 fibrils immediately after secretion. Biochem. Biophys. Res. Commun. 2002, 290:743-748.
5. Sabatelli P., et al. Expression of the collagen VI alpha5 and alpha6 chains in normal human skin and in skin of patients with collagen VI-related myopathies. J. Invest. Dermatol. 2011, 131:99-107.
6. Sabatelli P., et al. Expression of collagen VI alpha5 and alpha6 chains in human muscle and in Duchenne muscular dystrophy-related muscle fibrosis. Matrix Biol. 2012, 31:187-196.
7. Fitzgerald J., et al. Three novel collagen VI chains, alpha4(VI), alpha5(VI), and alpha6(VI). J. Biol. Chem. 2008, 283:20170-20180.
8. Gara S.K., et al. Three novel collagen VI chains with high homology to the alpha3 chain. J. Biol. Chem. 2008, 283:10658-10670.
9. Allen J.M., et al. Mice lacking the extracellular matrix protein WARP develop normally but have compromised peripheral nerve structure and function. J. Biol. Chem. 2009, 284:12020-12030.
10. Cheng J.S., et al. Collagen VI protects neurons against Abeta toxicity. Nat. Neurosci. 2009, 12:119-121.
11. Luther D.J., et al. Absence of type VI collagen paradoxically improves cardiac function, structure, and remodeling after myocardial infarction. Circ. Res. 2012, 110:851-856.
12. Iyengar P., et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J. Clin. Invest. 2005, 115:1163-1176.
13. Keene D.R., et al. Ultrastructure of type VI collagen in human skin and cartilage suggests an anchoring function for this filamentous network. J. Cell Biol. 1988, 107:1995-2006.
14. Cheng I.H., et al. Collagen VI protects against neuronal apoptosis elicited by ultraviolet irradiation via an Akt/phosphatidylinositol 3-kinase signaling pathway. Neuroscience 2011, 183:178-188.
15. Grumati P., et al. Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat. Med. 2010, 16:1313-1320.
16. Park J., Scherer P.E. Adipocyte-derived endotrophin promotes malignant tumor progression. J. Clin. Invest. 2012, 122:4243-4256.
17. Spencer M., et al. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E1016-E1027.
18. Nanda A., et al. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res. 2004, 64:817-820.
19. Gramann M., et al. Prominent collagen type VI expression in juvenile angiofibromas. Histochem. Cell Biol. 2009, 131:155-164.
20. Motrescu E.R., et al. Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. Oncogene 2008, 27:6347-6355.
21. Arafat H., et al. Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. Surgery 2011, 150:306-315.
22. Fujita A., et al. Identification of COL6A1 as a differentially expressed gene in human astrocytomas. Genet. Mol. Res. 2008, 7:371-378.
23. Iyengar P., et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 2003, 22:6408-6423.
24. Ruhl M., et al. Soluble collagen VI drives serum-starved fibroblasts through S phase and prevents apoptosis via down-regulation of Bax. J. Biol. Chem. 1999, 274:34361-34368.
25. Irwin W.A., et al. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat. Genet. 2003, 35:367-371.
26. You W.K., et al. Collagen VI ablation retards brain tumor progression due to deficits in assembly of the vascular basal lamina. Am. J. Pathol. 2012, 180:1145-1158.
27. Han J., Daniel J.C. Biosynthesis of type VI collagen by glioblastoma cells and possible function in cell invasion of three-dimensional matrices. Connect. Tissue Res. 1995, 31:161-170.
28. Wright A., et al. The differential effect of endothelial cell factors on in vitro motility of malignant and non-malignant cells. Ann. Biomed. Eng. 2008, 36:958-969.
29. Chiu K.H., et al. Quantitative secretome analysis reveals that COL6A1 is a metastasis-associated protein using stacking gel-aided purification combined with iTRAQ labeling. J. Proteome Res. 2011, 10:1110-1125.
30. Trueb B., Odermatt B.F. Loss of type VI collagen in experimental and most spontaneous human fibrosarcomas. Int. J. Cancer 2000, 86:331-336.
31. Min/+ mice. Carcinogenesis 2008, 29:1421-1427.
32. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
33. Sollberg S., et al. Presence of type I and VI collagen mRNAs in endothelial cells in cutaneous neurofibromas. Lab. Invest. 1991, 65:237-242.
34. Paulus W., et al. Immunohistochemical investigation of collagen subtypes in human glioblastomas. Virchows Arch. A: Pathol. Anat. Histopathol. 1988, 413:325-332.
35. Huang F.J., et al. Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse. Dev. Biol. 2010, 344:1035-1046.
36. Wu Y., et al. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15:416-428.
37. Chen J., et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011, 19:541-555.
38. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
39. Ruffell B., et al. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012, 33:119-126.
40. Chen P., et al. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin. Cancer Res. 2011, 17:7230-7239.
41. Chen P., Bonaldo P. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Int. Rev. Cell Mol. Biol. 2013, 301:1-35.
42. Gualandi F., et al. Macrophages: a minimally invasive tool for monitoring collagen VI myopathies. Muscle Nerve 2011, 44:80-84.
43. Schnoor M., et al. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J. Immunol. 2008, 180:5707-5719.
44. Tulla M., et al. Selective binding of collagen subtypes by integrin alpha 1I, alpha 2I, and alpha 10I domains. J. Biol. Chem. 2001, 276:48206-48212.
45. Tillet E., et al. NG2 proteoglycan mediates beta1 integrin-independent cell adhesion and spreading on collagen VI. J. Cell. Biochem. 2002, 86:726-736.
46. Burg M.A., et al. Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J. Biol. Chem. 1996, 271:26110-26116.
47. Barkan D., Chambers A.F. β1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin. Cancer Res. 2011, 17:7219-7223.
48. Son Y.O., et al. Cadmium induces carcinogenesis in BEAS-2B cells through ROS-dependent activation of PI3K/AKT/GSK-3beta/beta-catenin signaling. Toxicol. Appl. Pharmacol. 2012, 264:153-160.
49. Kim Y.J., et al. NDRG2 expression decreases with tumor stages and regulates TCF/β-catenin signaling in human colon carcinoma. Carcinogenesis 2009, 30:598-605.
50. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
51. Trujillo K.A., et al. Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int. J. Cancer 2011, 129:1310-1321.
52. Scherer P.E., et al. Cloning of cell-specific secreted and surface proteins by subtractive antibody screening. Nat. Biotechnol. 1998, 16:581-586.
53. Khan T., et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol. Cell. Biol. 2009, 29:1575-1591.
54. Vucenik I., Stains J.P. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann. N. Y. Acad. Sci. 2012, 1271:37-43.
55. Wiseman B.S., Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002, 296:1046-1049.
56. Benoit Y.D., et al. RGD-dependent epithelial cell-matrix interactions in the human intestinal crypt. J. Signal. Transduct. 2012, 2012:248759.
57. Symoens S., et al. Identification of binding partners interacting with the alpha1-N-propeptide of type V collagen. Biochem. J. 2011, 433:371-381.
58. Minamitani T., et al. Deficiency of tenascin-X causes a decrease in the level of expression of type VI collagen. Exp. Cell Res. 2004, 297:49-60.
59. Dangi-Garimella S., et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2011, 71:1019-1028.
60. Aoudjit F., Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract. 2012, 2012:283181.
61. Sherman-Baust C.A., et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003, 3:377-386.
62. Faller W.J., et al. Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. Melanoma Res. 2010, 20:392-400.
63. Varma R.R., et al. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol. Rep. 2005, 14:925-932.
64. Lindenberg J.J., et al. Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. Immunotherapy 2011, 3:77-96.
65. Schmid M.C., et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011, 19:715-727.
66. Nakasone E.S., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.
67. DeNardo D.G., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
68. De P.M., Lewis C.E. Cancer: macrophages limit chemotherapy. Nature 2011, 472:303-304.
69. Shree T., et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011, 25:2465-2479.
70. Zheng Y., et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2013, 27:702-710.
71. Jinushi M., et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12425-12430.
72. Atabai K., et al. Mfge8 diminishes the severity of tissue fibrosis in mice by binding and targeting collagen for uptake by macrophages. J. Clin. Invest. 2009, 119:3713-3722.
73. Tserel L., et al. MicroRNA expression profiles of human blood monocyte-derived dendritic cells and macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4. J. Biol. Chem. 2011, 286:26487-26495.
74. Kim T.H., et al. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 2010, 57:734-743.
75. Wang W., et al. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 2012, 33:1113-1120.
76. Zhang C., et al. miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2. PLoS ONE 2012, 7:e46090.
77. Squadrito M.L., et al. miR-511-3p modulates genetic programs of tumor-associated macrophages. Cell Rep. 2012, 1:141-154.
78. Burchardt E.R., et al. Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clin. Exp. Dermatol. 2003, 28:515-520.
79. Makawita S., et al. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol. Cell. Proteomics 2011, 10:M111.
80. Doane K.J., et al. Identification and functional characterization of two type VI collagen receptors, alpha 3 beta 1 integrin and NG2, during avian corneal stromal development. Invest. Ophthalmol. Vis. Sci. 1998, 39:263-275.
81. Leitinger B. Transmembrane collagen receptors. Annu. Rev. Cell Dev. Biol. 2011, 27:265-290.
82. Iida J., et al. Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res. 1995, 55:2177-2185.
83. Dorner M., et al. β1 integrin expression increases susceptibility of memory B cells to Epstein-Barr virus infection. J. Virol. 2010, 84:6667-6677.
84. Moransard M., et al. NG2 expressed by macrophages and oligodendrocyte precursor cells is dispensable in experimental autoimmune encephalomyelitis. Brain 2011, 134:1315-1330.
85. Mocsai A., et al. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat. Immunol. 2006, 7:1326-1333.
86. Slaughter D.P., et al. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6:963-968.
87. Hu B., et al. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 2012, 149:1207-1220.
88. Ismail R.S., et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 2000, 60:6744-6749.